NexoBrid
Eschar removal in deep partial- and full-thickness thermal burns
Key Facts
About MediWound
MediWound is a commercial-stage biopharmaceutical company specializing in advanced wound care and burn management. Its lead product, NexoBrid, is a topically administered, botanical proteolytic enzyme approved for the rapid and selective removal of eschar in deep partial- and full-thickness thermal burns. The company leverages its proprietary enzymatic technology platform to develop novel therapeutics for severe burns and other hard-to-heal wounds, aiming to improve patient outcomes and reduce healthcare costs. MediWound's strategy involves expanding the indications for its existing products and advancing its pipeline through clinical development and strategic partnerships.
View full company profileAbout MediWound
MediWound is a commercial-stage biopharmaceutical company specializing in advanced wound care and burn management. Its lead product, NexoBrid, is a topically administered, botanical proteolytic enzyme approved for the rapid and selective removal of eschar in deep partial- and full-thickness thermal burns. The company leverages its proprietary enzymatic technology platform to develop novel therapeutics for severe burns and other hard-to-heal wounds, aiming to improve patient outcomes and reduce healthcare costs. MediWound's strategy involves expanding the indications for its existing products and advancing its pipeline through clinical development and strategic partnerships.
View full company profileAbout MediWound
MediWound is a commercial-stage biopharmaceutical company specializing in advanced wound care and burn management. Its lead product, NexoBrid, is a topically administered, botanical proteolytic enzyme approved for the rapid and selective removal of eschar in deep partial- and full-thickness thermal burns. The company leverages its proprietary enzymatic technology platform to develop novel therapeutics for severe burns and other hard-to-heal wounds, aiming to improve patient outcomes and reduce healthcare costs. MediWound's strategy involves expanding the indications for its existing products and advancing its pipeline through clinical development and strategic partnerships.
View full company profile